Eidos Therapeutics Inc $ 89.71 -3.44 (-3.69%)
Volume:
95,582
Avg Vol (1m):
292,024
Market Cap $:
3.47 Bil
Enterprise Value $:
3.34 Bil
P/E (TTM):
0.00
P/B:
28.18
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 6.86 | ||
| Equity-to-Asset | 0.76 | ||
| Debt-to-Equity | 0.18 | ||
| Debt-to-EBITDA | -0.22 | ||
| Piotroski F-Score | 2 | ||
| Altman Z-Score | 53.55 | ||
| Beneish M-Score | -73.35 | ||
Profitability Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -78625.2 | ||
| Net Margin % | -79392.91 | ||
| ROE % | -64.44 | ||
| ROA % | -53.67 | ||
| ROC (Joel Greenblatt) % | -1905.29 | ||
| 3-Year EBITDA Growth Rate | -103.1 | ||
| 3-Year EPS without NRI Growth Rate | -73 |
EIDX
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 28.18 | ||
| PS Ratio | 29903.34 | ||
| EV-to-EBIT | -33.87 | ||
| EV-to-EBITDA | -33.98 | ||
| EV-to-Revenue | 26319.76 | ||
| Current Ratio | 11.1 | ||
| Quick Ratio | 11.1 | ||
| Days Payable | 347.63 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -24.8 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 28.21 | ||
| Earnings Yield (Greenblatt) % | -2.95 |